Mergers & acquisitions
Many investors and analysts expect that the changes to the corporate tax code will lead to increased merger and acquisition activity in 2018.
Lilly’s CEO noted at JPM that the recent tax changes should free up cash for more M&As.
The portfolio consists of acute, chronic and oncology products.
A look at why these two biopharma companies could have targets on their backs.
Fosun Pharma acquired China rights to market a novel treatment for Parkinson’s disease from Bial in an $18M agreement. BIAL developed Ongentys as a once-daily adjunctive therapy to levodopa/DOPA decarboxylase inhibitors.
Nestle submitted the highest offer and Merck was likely to select a winner during the first quarter, but might also choose not to sell the assets after all.
GlaxoSmithKline CEO Emma Walmsley is eying a big acquisition to spur revenue growth but is making sure that her company will not overpay.
Investors and analysts, after all, had been speculating, even nagging, on who the company should buy for several years.
MabVax’s antibody-based radioimmunotherapy product MVT-1075 is currently being tested on 22 patients with CA19-9 positive malignancies in a Phase I trial.
Since the acquisition fell apart, Allergan has fallen on some hard times.
PRESS RELEASES